Dipeptidyl peptidase-4 (DPP-4) inhibitors

DRUG3 trials

Sponsors

Janssen Research & Development, LLC, Canadian Network for Observational Drug Effect Studies, CNODES

Conditions

All-Cause MortalityCardiovascular DeathCardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic KetoacidosisHeart FailureIschemic StrokeLower Extremity Amputation

Unknown Phase

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

CompletedNCT03492580

Janssen Research & Development, LLCCardiovascular Diseases, Diabetes Mellitus, Type 2

Start: 2018-02-22End: 2018-06-25Updated: 2025-06-25

Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events

CompletedNCT03939624

Canadian Network for Observational Drug Effect Studies, CNODESAll-Cause Mortality, Cardiovascular Death, Heart Failure +3

Start: 2018-10-01End: 2019-10-01Updated: 2024-09-19

Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes

CompletedNCT04017221

Canadian Network for Observational Drug Effect Studies, CNODESDiabetes Mellitus, Type 2, Diabetic Ketoacidosis, Lower Extremity Amputation +1

Start: 2018-10-01End: 2019-12-01Updated: 2024-09-19

Related Papers

Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study

BMJ2020-09-23117 citations

Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study.

2020-07-28131 citations